A Strategic Step in the Healthcare Environment: Optum Acquires Amedisys for $3 Billion in Cash

In a significant development in the healthcare industry, Optum, a leading health services company, has announced its acquisition of Amedisys for a staggering $3.3 billion in cash. The deal, subject

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now
to approval from Amedisys shareholders, regulators, and other closing conditions, marks a strategic move in the evolving landscape of home health, hospice, and high-acuity care services.

Optum's acquisition of Amedisys solidifies its position as a key player in the healthcare industry. Amedisys, a well-established provider of home health, hospice, and high-acuity care, holds a prominent market position, making it an attractive target for Optum's expansion strategy. Under the terms of the agreement, Optum will acquire Amedisys' outstanding common stock for $101 per share in an all-cash transaction, totaling $3.3 billion.

The acquisition of Amedisys aligns with Optum's broader goal of diversifying its healthcare offerings and expanding its presence in the rapidly growing home health and hospice care markets. By combining Optum's extensive resources, technological capabilities, and deep industry expertise with Amedisys' established network and operational excellence, the merged entity aims to enhance patient care, improve outcomes, and create long-term value for shareholders.

Prior to the deal with Optum, Amedisys had entered into a merger agreement with Option Care Health, which was subsequently terminated. As part of the termination agreement, Amedisys paid a $106 million termination fee to Option Care Health. The termination of the merger agreement with Option Care Health allowed Amedisys to pursue the more lucrative offer from Optum.

The financial aspects of the acquisition are crucial to the success of the deal. In line with this, Amedisys' Compensation Committee approved one-time equity award grants for CEO Richard Ashworth and CFO Scott Ginn. These grants, in the form of time-based restricted stock units, are valued at $2.5 million and $1.5 million, respectively, and will vest over three years. Additionally, Ashworth and Ginn have committed to remain with the company following the merger.

The bid for Amedisys by both Option Care Health and Optum highlights the growing interest in home health, hospice, and high-acuity care services. The healthcare industry is witnessing a shift towards providing comprehensive care solutions outside traditional hospital settings. This acquisition positions Optum to capitalize on this trend and further solidifies its competitive advantage in the market.

Optum's acquisition of Amedisys represents a significant move in the healthcare industry, expanding Optum's presence in the home health and hospice care sectors.